The hazard-ratio for ERRα was 0.87 (N = 3571 patients) (Figure 15 and Table 1) for relapse-free survival (RFS), highlighting that the expression of ERRα is a negative prognostic marker in patients with breast cancer. Here, ESRRA is linked to breast carcinoma.